Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Prospective, Randomized, Multicenter, Open-label, Central Assessor-blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam-avibactam (Atm-avi) ±Metronidazole (Mtz) Versus Meropenem±Colistin (Mer±Col) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo-β-lactamase (Mbl) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options

Trial Profile

A Phase 3 Prospective, Randomized, Multicenter, Open-label, Central Assessor-blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam-avibactam (Atm-avi) ±Metronidazole (Mtz) Versus Meropenem±Colistin (Mer±Col) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo-β-lactamase (Mbl) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options

Suspended
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2019

At a glance

  • Drugs Avibactam/aztreonam (Primary) ; Colistin; Meropenem; Metronidazole
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms REVISIT
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jan 2019 Planned End Date changed from 1 Sep 2021 to 24 Sep 2021.
    • 03 Jan 2019 Planned primary completion date changed from 1 Sep 2021 to 7 Sep 2021.
    • 19 Dec 2018 Planned End Date changed from 22 Oct 2022 to 1 Sep 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top